Dimensional Fund Advisors’s Monte Rosa Therapeutics GLUE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$16.5M Buy
1,381,344
+203,856
+17% +$3.49M ﹤0.01% 2103
2026
Q2
$28.5M Buy
1,177,488
+136,116
+13% +$2.57M 0.01% 1875
2026
Q1
$17.1M Buy
1,041,372
+473,005
+83% +$9.05M ﹤0.01% 2041
2025
Q4
$8.91M Sell
568,367
-63,815
-10% -$860K ﹤0.01% 2321
2025
Q3
$4.68M Buy
632,182
+184,020
+41% +$975K ﹤0.01% 2562
2025
Q2
$2.02M Buy
448,162
+185,172
+70% +$826K ﹤0.01% 2756
2025
Q1
$1.22M Buy
262,990
+118,179
+82% +$725K ﹤0.01% 2841
2024
Q4
$1M Buy
144,811
+5,538
+4% +$41.6K ﹤0.01% 2914
2024
Q3
$738K Sell
139,273
-14,485
-9% -$73.1K ﹤0.01% 2961
2024
Q2
$575K Buy
153,758
+81,083
+112% +$413K ﹤0.01% 3006
2024
Q1
$512K Buy
72,675
+48,362
+199% +$287K ﹤0.01% 3038
2023
Q4
$137K Sell
24,313
-12,971
-35% -$50.9K ﹤0.01% 3245
2023
Q3
$179K Buy
37,284
+16
+0% +$103 ﹤0.01% 3231
2023
Q2
$255K Hold
37,268
– – ﹤0.01% 3196
2023
Q1
$290K Buy
+37,268
New +$259K ﹤0.01% 3128

Other funds holding GLUE

Dimensional Fund Advisors's GLUE Position: Q3 2026 in Review

Dimensional Fund Advisors increased its Monte Rosa Therapeutics (GLUE) stake by 17% in Q3 2026, buying an estimated $3.49M and bringing the position to 1,381,344 shares worth $16.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2103.

Dimensional Fund Advisors first reported a position in GLUE in Q1 2023 and has held it in 15 quarters since. The position peaked at $28.5M in Q2 2026. 39 funds tracked by Wall St. Rank hold GLUE as of Q3 2026.

  • Dimensional Fund Advisors held 1,381,344 shares of Monte Rosa Therapeutics worth $16.5M as of Q3 2026.
  • Dimensional Fund Advisors bought 203,856 Monte Rosa Therapeutics shares in Q3 2026, an estimated $3.49M.
  • Monte Rosa Therapeutics made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q3 2026, its #2103 holding.
  • Dimensional Fund Advisors first reported a position in Monte Rosa Therapeutics in Q1 2023 and has held it in 15 quarters since.
  • Dimensional Fund Advisors's Monte Rosa Therapeutics position peaked at $28.5M in Q2 2026.
  • 39 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q3 2026.

Based on Dimensional Fund Advisors's 13F filing for Q3 2026, filed 4 Nov 2026.